journal
MENU ▼
Read by QxMD icon Read
search

Bone Marrow Transplantation

journal
https://www.readbyqxmd.com/read/29988063/patient-eligibility-for-hematopoietic-stem-cell-transplantation-a-review-of-patient-associated-variables
#1
J Tay, A Daly, K Jamani, L Labelle, L Savoie, D Stewart, J Storek, S Beattie
Assessing patient eligibility for hematopoietic stem cell transplantation (HSCT) remains a complex, multifaceted challenge. Among these challenges, the paucity of comprehensive clinical data to guide decision making remains problematic coupled with unclear trade-offs between patient, disease and local HSCT center factors. Moreover, it is unclear that the modification of poor patient characteristics will improve post-HSCT outcomes. However, the use of Comorbidity Indices and Comprehensive Geriatric Assessments helps meet this challenge, but may be limited by overlapping patient characteristics...
July 9, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29988062/utilization-of-hematopoietic-stem-cell-transplantation-for-the-treatment-of-multiple-myeloma-a-mayo-stratification-of-myeloma-and-risk-adapted-therapy-msmart-consensus-statement
#2
REVIEW
Wilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, P Leif Bergsagel, Asher A Chanan Khan, David Dingli, Angela Dispenzieri, Rafael Fonseca, Susan R Hayman, Prashant Kapoor, Taxiarchis V Kourelis, Martha Q Lacy, Jeremy T Larsen, Eli Muchtar, Craig B Reeder, Taimur Sher, A Keith Stewart, Rahma Warsame, Ronald S Go, Robert A Kyle, Nelson Leung, Yi Lin, John A Lust, Stephen J Russell, Stephen R Zeldenrust, Amie L Fonder, Yi L Hwa, Miriam A Hobbs, Angela A Mayo, William J Hogan, S Vincent Rajkumar, Shaji K Kumar, Morie A Gertz, Vivek Roy
Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our multidisciplinary group of over 30 Mayo Clinic physicians with a special interest in the care of patients with MM and provide evidence-based recommendations on the use of HSCT in MM...
July 9, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29988061/haploidentical-versus-matched-donor-stem-cell-transplantation-for-patients-with-hematological-malignancies-a-systemic-review-and-meta-analysis
#3
Bo Yang, Ruili Yu, Lili Cai, Bin Guo, Hongfei Chen, Haomin Zhang, Peifeng He, Xuechun Lu
We compared the safety and efficacy of haploidentical stem cell transplantation (haplo-SCT) to matched donor SCT (matched-SCT) in treating hematological malignancies. The Medline, Cochrane, EMBASE, and Google Scholar databases were searched through 21 June 2017 using the search term "(hematological disease) AND matched AND (haploidentical OR haplo-identical OR haplo identical OR haplo transplantation OR haplo transplant OR haplo-SCT OR haplo-HSCT OR haplo-HCT)." Twenty-five studies enrolling 11,359 patients (haplo-SCT: 2677; matched-SCT: 8682) were included...
July 9, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29973659/sex-matters
#4
REVIEW
Shaun McCann
No abstract text is available yet for this article.
July 4, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29959437/a-prospective-study-of-allogeneic-transplantation-from-unrelated-donors-for-chronic-granulomatous-disease-with-target-busulfan-based-reduced-intensity-conditioning
#5
LETTER
Tomoo Osumi, Daisuke Tomizawa, Toshinao Kawai, Mayumi Sako, Eisuke Inoue, Tetsuya Takimoto, Eiichiro Tamura, Toru Uchiyama, Ken-Ichi Imadome, Maki Taniguchi, Ryota Shirai, Masanori Yoshida, Rie Ando, Yusuke Tsumura, Hiroshi Fuji, Kana Matsumoto, Yoko Shioda, Chikako Kiyotani, Keita Terashima, Masafumi Onodera, Kimikazu Matsumoto, Motohiro Kato
No abstract text is available yet for this article.
June 29, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29959436/allogeneic-hematopoietic-stem-cell-transplantation-for-children-and-adolescents-with-high-risk-cytogenetic-aml-distinctly-poor-outcomes-of-fus-erg-positive-cases
#6
Daisuke Tomizawa, Masanori Yoshida, Tadakazu Kondo, Takako Miyamura, Takashi Taga, Souichi Adachi, Katsuyoshi Koh, Maiko Noguchi, Harumi Kakuda, Kenichiro Watanabe, Yuko Cho, Takahiro Fukuda, Motohiro Kato, Norio Shiba, Hiroaki Goto, Keiko Okada, Masami Inoue, Yoshiko Hashii, Yoshiko Atsuta, Hiroyuki Ishida
Allocating patients with acute myeloid leukemia and high-risk cytogenetic abnormalities (HR-AML) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) is part of the standard treatment protocol; however, whether allo-HSCT truly improves the outcomes in these patients is debatable. Data on 169 children and adolescents with HR-AML who received their first allo-HSCT in first or second remission between 2000 and 2015 were extracted from a nationwide, Japanese HSCT registry. The 3-year disease-free survival (DFS) and overall survival (OS) rates were 55...
June 29, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29950664/clinical-and-genotypic-cmv-drug-resistance-in-hsct-recipients-a-single-center-epidemiological-and-clinical-data
#7
LETTER
Vejrazkova Eva, Pliskova Lenka, Hubacek Petr, Kostal Milan, Zavrelova Alzbeta, Radocha Jakub, Kutova Radka, Stepanova Vlasta, Zak Pavel
No abstract text is available yet for this article.
June 27, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29942002/ikaros-family-zinc-finger-1-mutation-is-an-independent-factor-for-the-poor-prognosis-of-adult-b-cell-acute-lymphoblastic-leukemia-and-allogeneic-hematopoietic-stem-cell-transplantation-can-improve-clinical-outcomes
#8
Shanhao Tang, Hongjie Shen, Changju Qu, Haiping Dai, Xiaming Zhu, Shengli Xue, Zixuan Ding, Jing Lu, Depei Wu, Xiaowen Tang
To investigate the prognosis of patients with adult B-cell acute lymphoblastic leukemia (B-ALL) with Ikaros family zinc-finger 1 (IKZF1) mutation and determine the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in improving the clinical outcome, we detected the IKZF1 mutation and BCR-ABL fusion gene at diagnosis in the bone marrow of 164 adult patients with B-ALL, and analyzed the clinical data of these patients retrospectively. Our analysis showed that grade III-IV acute graft-versus-host disease and IKZF1 mutation in the transplantation group and age and IKZF1 mutation in the non-transplantation group were independent factors for poor prognosis by univariate and multivariate analyses...
June 25, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29930402/net-reclassification-improvement-with-serial-biomarkers-and-bed-sided-spirometry-to-early-predict-the-need-of-organ-support-during-the-early-post-transplantation-in-hospital-stay-in-allogeneic-hct-recipients
#9
S D Braun, M Kuhn, S Bergmann, S Katzke, M Weise, N Alakel, F Stölzel, F Kroschinsky, G Ehninger, G Höffken, M Bornhäuser
To predict the need of intensive care unit admission with organ support during the transplantation hospital stay in 101 consecutives allogeneic hematopoietic cell transplantation (allo-HCT) recipients the added predictive utility of three times per week Copeptin, MR-proADM, MR-proANP, NT-proBNP, IL-6, Procalcitonin, D-dimer and three times per week bed-sided pulmonary function test was determined in comparison with an index model. The index model was calculated by multivariate regression analysis out of the patients' routine laboratory parameters...
June 21, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29915217/prospective-trial-of-minimal-residual-disease-assessment-by-multiparametric-flow-cytometry-for-multiple-myeloma-in-the-era-of-bortezomib-based-chemotherapy
#10
LETTER
C Amos Clark, Claudio A Mosse, Heidi Chen, Michael Byrne, Wichai Chinratanalab, Brian G Engelhardt, Stacey A Goodman, Shelton L Harrell, Adetola A Kassim, Bipin N Savani, Salyka Sengsayadeth, Madan Jagasia, R Frank Cornell
No abstract text is available yet for this article.
June 18, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29915216/pharmacokinetics-of-fludarabine-and-its-association-with-clinical-outcomes-in-paediatric-haematopoietic-stem-cell-transplantation-patients
#11
Hyewon Chung, Kyung Taek Hong, Ji Won Lee, Su-Jin Rhee, Seokuee Kim, Seo Hyun Yoon, Kyung-Sang Yu, Hyoung Jin Kang
Fludarabine is used as a common component of conditioning regimens for haematopoietic stem cell transplantation (HSCT). However, knowledge regarding the pharmacokinetic characteristics of once-daily fludarabine dosing in children is limited. This study investigated the pharmacokinetics of fludarabine and evaluated its associations with clinical outcomes in paediatric patients. A total of 802 blood samples obtained from 43 paediatric patients who underwent HSCT were included in a population pharmacokinetic analysis using non-linear mixed-effects modelling...
June 18, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29907807/availability-of-hla-allele-matched-unrelated-donors-estimation-from-haplotype-frequency-in-the-japanese-population
#12
Satoshi Nishiwaki, Hidenori Tanaka, Hiroto Kojima, Shinichiro Okamoto
A human leukocyte antigen (HLA)-matched unrelated donor is the primary alternative donor for allogeneic hematopoietic cell transplantation in Japan. In considering an optimal donor registry size, the availability of HLA-matched donors is important. In this study, the probability of finding an HLA-A, -B, -C, and -DRB1 allele-matched donor was estimated using two different methods based on the haplotype frequencies in the Japanese population: an actual measurement method (AMM) and a formula method (FM). According to AMM, the probabilities of finding an HLA-matched donor were 40...
June 15, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29907806/final-outcomes-of-escalated-melphalan-280-mg-m-2-with-amifostine-cytoprotection-followed-autologous-hematopoietic-stem-cell-transplantation-for-multiple-myeloma-high-cr-and-vgpr-rates-do-not-translate-into-improved-survival
#13
Parameswaran Hari, Donna E Reece, Jasleen Randhawa, Neal Flomenberg, Dianna S Howard, Ashrof Z Badros, Aaron P Rapoport, Barry R Meisenberg, Joanne Filicko-Ohara, Gordon L Phillips, David H Vesole
The most common preparative regimen for autologous transplantation (ASCT) in myeloma (MM) consists of melphalan 200 mg/m2 (MEL 200). Higher doses of melphalan 220-260 mg/m2 , although relatively well tolerated, have not shown significant improvement in clinical outcomes. Several approaches have been pursued in the past to improve CR rates, including poly-chemotherapy preparative regimens, tandem ASCT, consolidation, and/or maintenance therapy. Since there is a steep dose-response effect for intravenous melphalan, we evaluated an alternative single ASCT strategy using higher-dose melphalan at 280 mg/m2 (MEL 280) with amifostine as a cytoprotectant as the maximum tolerated dose determined in an earlier phase I dose escalation trial...
June 15, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29907805/extracorporeal-photopheresis-is-a-valuable-treatment-option-in-steroid-refractory-or-steroid-dependent-acute-graft-versus-host-disease-experience-with-three-different-approaches
#14
LETTER
Marietta Nygaard, Tonny Karlsmark, Niels Smedegaard Andersen, Ida Marianne Schjødt, Søren Lykke Petersen, Lone Smidstrup Friis, Brian Thomas Kornblit, Henrik Sengeløv
No abstract text is available yet for this article.
June 15, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29904128/high-gastrointestinal-microbial-diversity-and-clinical-outcome-in-graft-versus-host-disease-patients
#15
REVIEW
Florent Malard, Cyrielle Gasc, Emilie Plantamura, Joël Doré
No abstract text is available yet for this article.
June 14, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29904127/strategies-to-enhance-the-graft-versus-tumour-effect-after-allogeneic-haematopoietic-stem-cell-transplantation
#16
Eric Wong, Joanne E Davis, Andrew Grigg, Jeff Szer, David Ritchie
Relapse of haematological malignancies after allogeneic haematopoietic stem cell transplant is a major cause of mortality. The immunological mechanisms that may lead to disease relapse may include immunological immaturity prior to reconstitution of the allogeneic immune system, tumour antigen downregulation or promotion of T-cell exhaustion by interactions with the tumour microenvironment. Current therapeutic strategies for post-transplant relapse are limited in their efficacy and alternative approaches are required...
June 14, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29899574/pre-engraftment-cytomegalovirus-dnaemia-in-allogeneic-hematopoietic-stem-cell-transplant-recipients-incidence-risk-factors-and-clinical-outcomes
#17
Carlos Solano, Estela Giménez, Eliseo Albert, Eva María Mateo, Montserrat Gómez, Rosa Goterris, Ariadna Pérez, Paula Amat, Juan Carlos Hernández-Boluda, Marc Poch, José Luis Piñana, David Navarro
To gauge the risk of delaying initiation of prophylaxis with letermovir from the time of donor infusion to prevent CMV infection in allo-HSCT recipients we investigated the clinical outcomes of CMV DNAemia episodes occurring before engraftment, and compared to that of episodes developing after engraftment (up to day +365). A total of 197 consecutive adult patients were included. Plasma CMV DNA load was monitored by real-time PCR assays [limit of detection: 31 IU/ml]. A total of 150 out of 197 patients had CMV DNAemia (cumulative incidence of 77%; 95% CI, 73-81%), and 38 out of the 197 patients developed it before engraftment (cumulative incidence, 19%; 95% CI, 10-30...
June 13, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29899573/use-of-defibrotide-to-treat-adult-patients-with-transplant-associated-thrombotic-microangiopathy
#18
LETTER
M E Martínez-Muñoz, R Forés, A Lario, G Bautista, J L Bueno, C de Miguel, B Navarro, A De Laiglesia, A Sánchez-Guerrero, J R Cabrera, R F Duarte
No abstract text is available yet for this article.
June 13, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29899572/hematopoietic-stem-cell-transplantation-for-isolated-extramedullary-relapse-of-acute-lymphoblastic-leukemia-in-children
#19
Maria Gabelli, Marco Zecca, Chiara Messina, Elisa Carraro, Barbara Buldini, Attilio Maria Rovelli, Franca Fagioli, Alice Bertaina, Edoardo Lanino, Claudio Favre, Marco Rabusin, Arcangelo Prete, Mimmo Ripaldi, Walter Barberi, Fulvio Porta, Maurizio Caniglia, Stella Santarone, Paolo D'Angelo, Giuseppe Basso, Franco Locatelli
Relapse of acute lymphoblastic leukemia (ALL) may occur in extramedullary sites, mainly central nervous system (CNS) and testis. Optimal post-remissional treatment for isolated extramedullary relapse (IEMR) is still controversial. We collected data of children treated with hematopoietic stem cell transplantation (HSCT) for ALL IEMR from 1990 to 2015 in Italy. Among 281 patients, 167 had a relapse confined to CNS, 73 to testis, 14 to mediastinum, and 27 to other organs. Ninety-seven patients underwent autologous HSCT, 79 received allogeneic HSCT from a matched family donor, 75 from a matched unrelated donor, and 30 from an HLA-haploidentical donor...
June 13, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29899571/the-safety-and-efficacy-of-clofarabine-in-combination-with-high-dose-cytarabine-and-total-body-irradiation-myeloablative-conditioning-and-allogeneic-stem-cell-transplantation-in-children-adolescents-and-young-adults-caya-with-poor-risk-acute-leukemia
#20
Jessica Hochberg, Stacey Zahler, Mark B Geyer, Nan Chen, Jennifer Krajewski, Lauren Harrison, Olga Militano, M Fevzi Ozkaynak, Alexandra C Cheerva, Julie Talano, Theodore B Moore, Alfred P Gillio, Mark C Walters, Lee Ann Baxter-Lowe, Carl Hamby, Mitchell S Cairo
Acute leukemias in children with CR3, refractory relapse, or induction failure (IF) have a poor prognosis. Clofarabine has single agent activity in relapsed leukemia and synergy with cytarabine. We sought to determine the safety and overall survival in a Phase I/II trial of conditioning with clofarabine (doses 40 - 52 mg/m2 ), cytarabine 1000 mg/m2 , and 1200 cGy TBI followed by alloSCT in children, adolescents, and young adults with poor-risk leukemia. Thirty-seven patients; Age 12 years (1-22 years); ALL/AML: 34:3 (18 IF, 10 CR3, 13 refractory relapse); 15 related, 22 unrelated donors...
June 13, 2018: Bone Marrow Transplantation
journal
journal
20054
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"